F
Félix Gutiérrez
Researcher at Universidad Miguel Hernández de Elche
Publications - 321
Citations - 10243
Félix Gutiérrez is an academic researcher from Universidad Miguel Hernández de Elche. The author has contributed to research in topics: Population & Medicine. The author has an hindex of 48, co-authored 302 publications receiving 8638 citations. Previous affiliations of Félix Gutiérrez include Hospital General Universitario Gregorio Marañón & Carlos III Health Institute.
Papers
More filters
Journal ArticleDOI
Clinical evaluation of rapid point-of-care testing for detection of novel influenza A (H1N1) virus in a population-based study in Spain
V. Ortiz de la Tabla,Pedro Antequera,Mar Masiá,P. Ros,Coral Martin,Gregoria Gazquez,Fernando Buñuel,Victoria Sánchez,Catalina Robledano,Félix Gutiérrez +9 more
TL;DR: Although a positive RIDT performed well in predicting PCR-confirmed infection with pandemic H1N1 virus, the sensitivity was very low and a negative test result was a poor predictor of the absence of infection.
Journal ArticleDOI
Performance of Genotypic Algorithms for Predicting HIV-1 Tropism Measured against the Enhanced-Sensitivity Trofile Coreceptor Tropism Assay
TL;DR: Overall, the accuracy of the bioinformatics tools to detect CXCR4-using virus was similar for ES Trofile and Trofile; however, the negative predictive values for genotypic tools with ES Tro file were slightly higher than they were with Trofile.
Journal ArticleDOI
Mycobacterium marinum infection complicated by anti-tumour necrosis factor therapy.
TL;DR: P sporotrichoid spread of Mycobacterium marinum in a man with Crohn's disease treated with infliximab is described and may have a potential local spread and systemic dissemination in patients treated with TNF-alpha inhibitors.
Journal ArticleDOI
Differential Body Composition Effects of Protease Inhibitors Recommended for Initial Treatment of HIV Infection: A Randomized Clinical Trial
Esteban Martínez,Ana González-Cordón,Elena Ferrer,Pere Domingo,Eugenia Negredo,Félix Gutiérrez,Joaquín Portilla,Adria Curran,Daniel Podzamczer,Esteban Ribera,Javier Murillas,Jose I Bernardino,Ignacio Santos,José A. Carton,Joaquim Peraire,Judit Pich,Ramon Deulofeu,Ignacio Perez,José M. Gatell,Juan A. Arnaiz,Helena Beleta,David Garcia,Andrea Pejenaute,Nuria Ramos,P. Arcaina,L. Giner,S. Moya,M. Pampliega,J. Portilla,G. Barrera,D. Podzamczer,N. Rozas,Maria Saumoy,E. Ferrer,V. Asensi,J.A. Cartón,Gatell Jm,A. González-Cordón,I. Pérez,Esteban Martínez,Mar Masiá,Sergio Padilla,J.R. Ramos,Catalina Robledano,F. Gutiérrez,J. Puig,E. Negredo,Jose R. Arribas,J.M. Castro,J.I. Bernardino,José Sanz,I. Santos,Mireia Cairó,P. Velli,David Dalmau,A. Lamas,P. Martí-Belda,Fernando Dronda,José Ramón Blanco,M. Gutierrez,M. G. Mateo,P. Domingo,Elena Losada,A. Prieto,Antonio Antela,Javier Murillas,A. Aguilar,J. Peraire,Montserrat Vargas,Consuelo Viladés,F. Vidal,Manel Crespo,Adrian Curran,Esteve Ribera,J. A. Arnaiz,H. Beleta,Dácil García,A. Pejenaute,N. Ramos,J. Pich +79 more
TL;DR: No major differences were found in efficacy, clinically relevant side effects, or plasma cholesterol fractions between atazanavir/ritonavir and darunavir-based regimens for HIV-infected adults, however, atazAnavIR/rit onavir led to higher triglycerides and more total and subcutaneous fat than dar unavir/.
Journal ArticleDOI
Preemptive interleukin-6 blockade in patients with COVID-19.
Lucía Guillén,Sergio Padilla,Marta S. Fernández,Vanesa Agulló,José A. García,Guillermo Telenti,Javier García-Abellán,Ángela Botella,Félix Gutiérrez,Mar Masiá +9 more
TL;DR: Preliminary results suggest that tocilizumab, a humanized monoclonal anti-interleukin-6 receptor antibody, may be beneficial in severely ill patients, but no data are available on earlier stages of disease.